通过生物化学、分子生物学、生物物理学、细胞生物学等手段，围绕以下研究方向开展工作：

（1）血管内皮细胞稳态与血栓形成的调控机制研究（PECAM-1、Ang/Tie）

（2）凝血系统中水解酶的结构和功能研究（凝血因子VII和XI、血浆激肽酶）

（3）纤溶系统在肿瘤侵袭和转移中的调控研究（尿激酶-尿激酶受体）

（4）利用枯草芽孢杆菌作为模式生物研究细胞分化的调控机制

（5）体外诊断（IVD）原材料及诊断试剂盒的研发

生物化工、药理学、药物分析、制药工程

生物化工

2016.02 –至 今：福州大学化学学院，讲师-副教授-教授

2021.03 – 2023.02：国家自然科学基金委员会，流动编制业务主管

2018.10 – 2019.10：美国哈佛医学院，访问学者

（合作导师）

2014.07 – 2014.10：丹麦奥胡斯大学，访问学者

（合作导师）

2010.07 – 2016.01：中国科学院福建物质结构研究所，助理研究员

2005.09 - 2010.07：中国科学院福建物质结构研究所，生物化学与分子生物学，博士

（导师：黄明东研究员）

2001.09 - 2005.07：贵州大学，生物技术，学士

主要从事凝血与纤溶系统相关蛋白的结构和功能研究，并开发体外临床诊断技术、原材料及应用。以第一或通讯作者在ScienceAdvances, Critical Care, Pharmacological Research等国内外期刊发表学术论文42篇。主持3项国家自然科学基金及多项福建省科技创新重点项目、福建省自然科学基金、福建省高校产学研联合创新项目和技术转化项目等课题。获授权发明专利16项，其中专利转让3项。开展产学研合作，研发并获批体外诊断试剂盒注册证6本，其中全国独家注册证3本。

1.国家自然科学基金面上项目（32370990），2024-2027，项目负责人

2.国家自然科学基金面上项目（82070142），2021-2024，项目负责人

3.国家自然科学基金青年基金（31400637），2015-2017，项目负责人

4.福建省高校产学研联合创新项目（2023Y4016）,2023-2026，项目负责人

5.福建省科技创新重点项目（2021G02004），2022-2023，项目负责人

6.福建省自然科学基金面上项目（2018J01729），2018-2021，项目负责人

7.福建省自然科学基金青年创新项目（2012J05071），2012-2015，项目负责人

8.横向项目，2020-2023，项目负责人

9.横向项目，2023-2024，项目负责人

10.福建省双一流课程建设经费，2020-2025，项目负责人

11.国家重点研发计划项目（2023YFE0118400），2023-2026，研究骨干

12.国家重点研发计划项目（2017YFE0103200），2018-2021，研究骨干

1. 2024年中国国际大学生创新大赛金奖项目指导老师

2. 2024年福建省大学生创新大赛银奖项目指导老师

3. 2022年福建省优秀研究生学位论文指导老师

4. 2021年福州大学“厦航奖教奖”

5. 2020年福州大学“鸿耀奖教奖”

2025

100. Chen L, Lin Y, Ding S, Huang M*,Jiang L*. Recent Advances in Clinically Used and Trialed Photosensitizers for Antitumor Photodynamic Therapy.Mol Pharm.2025;22(7):3530-3541.

99. Mai Y, Zhou Y, Ye Q, Wang Z, Li C, Chen Y, Xiao H, Hu Y, Li J, Zhang W, Wang T, Lin H,Jiang L, Yuan C, Xu P*, Huang M*. Bacteria-responsive antimicrobial and hemostatic cellulose-based dressing for wound treatments.Int J Biol Macromol. 2025;315(Pt 1):144272.

98.Jiang L, Yuan C, Flaumenhaft R*, Huang M*. Recent advances in vascular thiol isomerases: insights into structures, functions in thrombosis and antithrombotic inhibitor development.Thromb J. 2025;23(1):16.

97. Xie S, Yang G, Wu J,Jiang L, Yuan C, Xu P, Huang M, Liu Y, Li J*. In silico screening of natural products as uPAR inhibitors via multiple structure-based docking and molecular dynamics simulations.J Biomol Struct Dyn.2025;43(6):3064-3075.

96. Zhou Y, Wang D, Wu J, Qi Y, Song M, Yao H, Liao CK, Lin H, Huang M, Zhuo D,Jiang L, Yuan C, Chen Y, Huang M*, Li J*, Xu P*. Discovery of the Low-Hemorrhagic Antithrombotic Effect of Montelukast by Targeting FXIa in Mice.Arterioscler Thromb Vasc Biol. 2025;45(4):e150-e162.

95. Wang R, Li H, Xie Z, Huang M, Xu P, Yuan C, Li J, Flaumenhaft R*, Huang M*,Jiang L*. Development of a recombinant Ang1 variant with enhanced Tie2 binding and its application to attenuate sepsis in mice.Science Advances.2025;11(3):eads1796.

94. Li H, Qu Y, Guo Z, Chen D,Jiang L, Xu P, Huang M*, Yuan C*. Dual modified ferritin nanocages for tumor-targeted and microenvironment-responsive drug delivery.Int J Biol Macromol.2025;303:140694.

93. Chen L, Li L, Zhao H, Li H, Li J, Li C, Zhou Y, Yang L, Liang J, Zhang H, Li J, Xu P, Yuan C, Liu Z, Huang M*,Jiang L*. Integration of EMAP-II-targeted anti-angiogenesis and photodynamic therapy using zinc phthalocyanine nanosystem for enhanced cancer treatment.Colloids Surf B Biointerfaces.2025;248:114493.

2024

92. Li J, Wang G, Mai Y, Zhang W, Zhao H, Zhou Y, Chen L, Lin Y,Jiang L, Xu P, Zhou X, Yuan C*, Huang M*. Lysosome-localization and tumor-targeting of novel photosensitizers enhance the ablation of cancer.J Photochem Photobiol B.2024;261:113045.

91. Li H, Wang R, Xu P, Yuan C, Huang M*,Jiang, L*. Elucidating the molecular basis of PECAM-1 and Tie2 interaction from binding dynamics and complex formation.Biochem Biophys Res Commun. 2024;735:150484.

90. Lin Y, Chen L,Jiang, L*, Huang M*, Recent advances in filter materials for efficient photodynamic inactivation of pathogens in the air.Journal of Environmental Chemical Engineering. 2024, 12(6), 114877

89. Lin H, Xu M,Jiang L, Yuan C, Jiang C, Huang M*, Li J*, Xu P*. Water-medicated specifically targeting the S1 pockets among serine proteases using an arginine analogue.Bioorg Chem. 2024;152:107734.

88. Chen Z, Chen J, Liu D, Chen J, Li L, Chen D, Chen N, Huang J, Chen Z, Xu P,Jiang L, Yuan C*, Jiang Y*, Huang M*. A Simple Phthalocyanine-Peptide Conjugate as Targeting Photosensitizer and Its Broad Applications in Health.Health and Metabolism, 2024, 3-3

87. Li W, Zhang S, Dang S, Gao L, Li G, Cheng D,Jiang L, Huang T, Zhai J*. Establishment of an A/T-Rich Specifically MGB Probe digital droplet PCR Assays Based on SNP for Brucella wild strains and vaccine strains.Diagn Microbiol Infect Dis. 2024;110(1):116432.

86. Chen S, Fang S, Zhou Y, Huang Z, Yu S, Chen D, Wang Z, Xu Y, Liu P, Li Y, Lin W,Jiang L, Yuan C*, Huang M*. A low bleeding risk thrombolytic agent: citPA5.Cardiovasc Res. 2024;120(10):1191-1201.

85. Xu Y, Hu Y, Wu G, Niu L, Fang C, Li Y,Jiang L, Yuan C*, Huang M*. Specific inhibition on PAI-1 reduces the dose of Alteplase for ischemic stroke treatment.International Journal of Biological Macromolecules.2024, 257.

84. Yan W, Li H, Ning J, Huang S,Jiang L, Xu P, Huang M*, Yuan C*. Engineered protein cages with enhanced extracellular drug release for elevated antitumor efficacy.Int J Biol Macromol. 2024;267(Pt 1):131492.

83. Chen L, Li X, Chen J, Lin R, Mai Y, Lin Y, Wang G, Chen Z, Zhang W, Wang J, Yuan C,Jiang L, Xu P*, Huang M*. Formulation with zinc acetate enhances curcumin's inherent and photodynamic antimicrobial effects for food preservation.Food Control.2024, 157, 110200.

82. Xu Y, Hu Y, Wu G, Niu L, Fang C, Li Y,Jiang L, Yuan C*, Huang M*. Specific inhibition on PAI-1 reduces the dose of Alteplase for ischemic stroke treatment.Int J Biol Macromol. 2024;257(Pt 2):128618.

81. Wei Y, Huang M*,Jiang L*. Advancements in Serine Protease Inhibitors: From Mechanistic Insights to Clinical Applications.Catalysts.2024. 14 (11), 787

2023

80. Zhao H, Huang M*,Jiang L*. Potential Roles and Future Perspectives of Chitinase 3-like 1 in Macrophage Polarization and the Development of Diseases.Int J Mol Sci.2023;24(22):16149.

79. Wang Y, Luo Z, Morelli X, Xu P,Jiang L*, Shi X*, Huang M*. Crystal structures of human serum albumin in complex with lysophosphatidylcholine.Biophys J.2023;122(21):4135-4143.

78. Mai Y, Wang Z, Zhou Y, Wang G, Chen J, Lin Y, Ji P, Zhang W, Jing Q, Chen L, Chen Z, Lin H,Jiang L, Yuan C, Xu P, Huang M. From disinfectants to antibiotics: Enhanced biosafety of quaternary ammonium compounds by chemical modification.J Hazard Mater. 2023;460:132454.

77. Liu D,Jiang L, Chen J, Chen Z, Yuan C*, Lin D*, Huang M*. Monomer and Oligomer Transition of Zinc Phthalocyanine Is Key for Photobleaching in Photodynamic Therapy.Molecules. 2023;28(12):4639.

76. Xu Y, Chen D, Liu P, Hu Y, Peng S, Chen S, Li Y, Lin W,Jiang L, Yuan C*, Huang M*. A triple fusion tissue-type plasminogen activator (TriF-ΔtPA) enhanced thrombolysis in carotid embolism-induced stroke model.Int J Pharm.2023;637:122878.

75. Li H, Wang Z, Yu S, Chen S, Zhou Y, Qu Y, Xu P,Jiang L, Yuan C*, Huang M*. Albumin-based drug carrier targeting urokinase receptor for cancer therapy.Int J Pharm. 2023;634:122636.

74. Zhou Y, Song M, Xie D, Yan S, Yu S, Xie S, Cai M, Li H, Shang L,Jiang L, Yuan C, Huang M*, Li J*, Xu P*. Structural Dynamics-Driven Discovery of Anticancer and Antimetastatic Effects of Diltiazem and Glibenclamide Targeting Urokinase Receptor.J Med Chem. 2023;66(8):5415-5426.

73. Zhou Y, Yu S, Chen D, Li H, Xu P, Yuan C,Jiang L^*, Huang M^*. Nafamostat Mesylate in Combination with the Mouse Amino-Terminal Fragment of Urokinase-Human Serum Albumin Improves the Treatment Outcome of Triple-Negative Breast Cancer Therapy.Mol Pharm.2023;20(2):905-917.

2022

72. Chen D, Liu Y, Liu P, Zhou Y,Jiang L, Yuan C*, Huang M*. Orally delivered rutin in lipid-based nano-formulation exerts strong antithrombotic effects by protein disulfide isomerase inhibition.Drug Deliv.2022;29(1):1824-1835.

71. Wang G, Yang L,Jiang L, Chen J, Jing Q, Mai Y, Deng L, Lin Y, Chen L, Chen Z, Xu P, Jiang L, Yuan C*, Huang M*. A new class of quaternary ammonium compounds as potent and environmental friendly disinfectants.J Clean Prod. 2022;379:134632.

70. Zhang, X; Sun, G; Yuan, C;Jiang, L*; Huang, M*. Structural Studies of Bypass of Forespore Protein C from Bacillus Subtilis to Reveal Its Inhibitory Molecular Mechanism for SpoIVB.Catalysts.2022, 12, 1530.

69. Lin Y, Chen J, Mai Y, Chen L, Chen Z, Wang G, Deng L, Xu P, Yuan C,Jiang L*, Huang M*. Double-Grafted PET Fiber Material to Remove Airborne Bacteria with High Efficiency.ACS Appl Mater Interfaces.2022;14(41):47003-47013.

68. Zhou Y, Wu J, Xue G, Li J,Jiang L*, Huang M*. Structural study of the uPA-nafamostat complex reveals a covalent inhibitory mechanism of nafamostat.Biophys J.2022:S0006-3495(22)00694-4.

67. Chen S, Yuan C,Jiang L, Luo Z, Huang M. Crystallographic analysis of interaction between cisplatin and human serum albumin: Effect of fatty acid.Int J Biol Macromol.2022;216:172-178.

66. Wang R, Yang M,Jiang L*, Huang M*. Role of Angiopoietin-Tie axis in vascular and lymphatic systems and therapeutic interventions.Pharmacol Res. 2022;182:106331.

65. Wang S, Wang Y, Liu Y, Liu L, Li J, Yang K, Liu M, Zeng W, Qin L, Lin R, Nie X,Jiang L, Wang S*. The regulatory role of the Aspergillus flavus core retromer complex in aflatoxin metabolism.J Biol Chem.2022;298(7):102120.

64. Chen J, Jing Q, Xu Y, Lin Y, Mai Y, Chen L, Wang G, Chen Z, Deng L, Chen J, Yuan C,Jiang L, Xu P*, Huang M*. Functionalized zinc oxide microparticles for improving the antimicrobial effects of skin-care products and wound-care medicines.Biomater Adv. 2022;135:212728.

63. Chen D, Liu P, Liu Y, Wang Z, Zhou Y,Jiang L, Yuan C, Li Y, Lin W, Huang M*. A Clot-Homing Near-Infrared Probe for In Vivo Imaging of Murine Thromboembolic Models.Adv Healthc Mater.2022;11(8):e2102213.

62. Yu S, Sui Y, Wang J, Li Y, Li H, Cao Y, Chen L,Jiang L, Yuan C*, Huang M*. Crystal structure and cellular functions of uPAR dimer.Nat Commun. 2022;13(1):1665.

61. S El Salamouni N, Buckley BJ,Jiang L, Huang M, Ranson M*, Kelso MJ*, Yu H*. Disruption of Water Networks is the Cause of Human/Mouse Species Selectivity in Urokinase Plasminogen Activator (uPA) Inhibitors Derived from Hexamethylene Amiloride (HMA).J Med Chem. 2022;65(3):1933-1945.

2021

60. Yu S, Sun G, Sui Y, Li H, Mai Y, Wang G, Zhang N, Bi Y, Gao GF, Xu P,Jiang L, Yuan C*, Yang Y*, Huang M*. Potent inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 by photosensitizers compounds.Dyes Pigm.2021;194:109570.

59. Sun G, Sui Y, Zhou Y, Ya J, Yuan C,Jiang L*, Huang M*. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.J Virol.2021;95(19):e0086121.

58.Ma H^#, Li R^#,Jiang L^#, Qiao S, Chen XX, Wang A, Zhang G. Structural comparison of CD163 SRCR5 from different species sheds some light on its involvement in porcine reproductive and respiratory syndrome virus-2 infection in vitro.Vet Res. 2021;52(1):97.

57. Zhang D, Chen J, Jing Q, Chen Z, Ullah A,Jiang L, Zheng K, Yuan C, Huang M. Development of a Potent Antimicrobial Peptide With Photodynamic Activity.Front Microbiol.2021;12:624465.

56. Sun G, Yang M,Jiang L*,Huang M*. Regulation of pro-σ^Kactivation: a key checkpoint in Bacillus subtilis sporulation.Environ Microbiol. 2021;23(5):2366-2373.

55. Yuan C, Guo Z, Yu S,Jiang L*, Huang M*. Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners.Drug Discov Today.2021;26(4):1076-1085.

54. Yu S, Sun G, Sui Y, Li H, Mai Y, Wang G, Zhang N, Bi Y, Gao GF, Xu P,Jiang L, Yuan C, Yang Y, Huang M. Potent inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 by photosensitizers compounds.Dyes Pigm.2021;194:109570.

53.Jiang L, Yuan C, Huang M. A general strategy to inhibit serine protease by targeting its autolysis loop.FASEB J.2021;35(2):e21259.

52.王蕊，黄美娟，许燕艳，袁彩，黄明东^*，江龙光^*，Ang-Tie轴在血管和淋巴系统相关疾病中作用的研究进展，生物工程学报,2021,37(8): 2633-2644.

51. Li L, Huang M, Shen J, Wang Y, Wang R, Yuan C*,Jiang L, Huang M. Serum Levels of Soluble Platelet Endothelial Cell Adhesion Molecule 1 in COVID-19 Patients Are Associated With Disease Severity.J Infect Dis. 2021;223(1):178-179.

2020

50. Huang M, Li L, Shen J, Wang Y, Wang R, Yuan C, Huang M*,Jiang L*. Plasma levels of the active form of suPAR are associated with COVID-19 severity.Crit Care.2020;24(1):704.

49. Xu Y, Chen S, Chen D, Peng S, Cheng Y, Li J, Li Y,Jiang L, Yuan C*, Huang M*. Recent progress in developing of thrombolytic agents for ischemic stroke.Sheng Wu Gong Cheng Xue Bao. 2020;36(10):2029-2039.

48. Zhao R, Fang Y, Chen Z, Le J,Jiang L, Shao J*. Self-assembled amphiphile-based nanoparticles for the inhibition of hepatocellular carcinoma metastasis via ICAM-1 mediated cell adhesion.Acta Biomater.2020;111:373-385.

47. Liang C, Chen D, Liao X,Jiang L, Yuan C*, Huang M*. Progress in the structural studies and inhibitor development of protein disulfide isomerase.Progress in Biochemistry and Biophysics,2020,47(7):595-606

46. G Xue, X Xie, Y Zhou, C Yuan, M Huang*,Jiang L*. Insight to the residue in P2 position prevents the peptide inhibitor from being hydrolyzed by serine proteases.Biosci Biotechnol Biochem.2020;84(6):1153-1159.

45. Jiang Y, Lin L, Chen S,Jiang L, Kriegbaum MC, Gårdsvoll H, Hansen LV, Li J, Ploug M, Yuan C*, Huang M*. Crystal Structures of Human C4.4A Reveal the Unique Association of Ly6/uPAR/α-neurotoxin Domain.Int J Biol Sci.2020;16(6):981-993.

44. Lin J, Fan L, Li B, Zhao R,Jiang L, Zhang B, Lu Y, Shao J*. A study to evaluate herb-drug interaction underlying mechanisms: An investigation of ginsenosides attenuating the effect of warfarin on cardiovascular diseases.Eur J Pharm Sci. 2020;142:105100.

43. Li L, Chen D, Zheng K,Jiang L, Dai T, Yang L, Jiang L, Chen Z, Yuan C*, Huang M*. Enhanced Antitumor Efficacy and Imaging Application of Photosensitizer-Formulated Paclitaxel.ACS Appl Mater Interfaces.2020;12(4):4221-4230.

42. Zhou Y, Chen D, Xue G, Yu S, Yuan C, Huang M*,Jiang L*. Improved therapeutic efficacy of quercetin-loaded polymeric nanoparticles on triple-negative breast cancer by inhibiting uPA.RSC Adv.2020;10(57):34517-34526.

2009-2019

41. Buckley BJ, Majed H, Aboelela A, Minaei E,Jiang L, Fildes K, Cheung CY, Johnson D, Bachovchin D, Cook GM, Huang M, Ranson M*, Kelso MJ*. 6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.Bioorg Med Chem Lett.2019;29(24):126753.

40. Zuo K, Qi Y, Yuan C,Jiang L, Xu P, Hu J, Huang M, Li J*. Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors.Cancer Metastasis Rev. 2019;38(3):507-524.

39. Xie X, Guo N, Xue, Xie D, Yuan C, Harrison J, Li J, L.Jiang L*, Huang M*. Solution structure of SpolVB reveals mechanism of PDZ domain-regulated protease activity.Frontiers in Microbiology, 2019;10,1232.

38.Jiang L, Xie X, Li J, Persson E*, Huang M*. Crystal structure, epitope, and functional impact of an antibody against a superactive FVIIa provide insights into allosteric mechanism.Res Pract Thromb Haemost. 2019;3(3):412-419.

37. Liu M, Lin L, Høyer-Hansen G, Ploug M, Li H,Jiang L, Yuan C, Li J, Huang M*. Crystal structure of the unoccupied murine urokinase-type plasminogen activator receptor (uPAR) reveals a tightly packed DII-DIII unit.FEBS Lett.2019;593(11):1236-1247.

36. Li R, Liang C,Jiang L, Yuan C, Huang M*. Structural determination of group A Streptococcal surface dehydrogenase and characterization of its interaction with urokinase-type plasminogen activator receptor.Biochem Biophys Res Commun. 2019;510(4):539-544.

35. Wang D, Yang Y,Jiang L, Wang Y, Li J, Andreasen PA, Chen Z, Huang M*, Xu P*. Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides.J Med Chem.2019;62(4):2172-2183.

34. Lin H, Chen J, Zhang Y, Ulla A, Liu J, Lin F,Jiang L, Huang M*. Enhanced anti-microbial effect through cationization of a mono-triazatricyclodecane substituted asymmetric phthalocyanine.J Inorg Biochem. 2018;189:192-198.

33. Sun YG, Li R,Jiang L, Qiao S, Zhi Y, Chen XX, Xie S, Wu J, Li X, Deng R, Zhang G*. Characterization of the interaction between recombinant porcine aminopeptidase N and spike glycoprotein of porcine epidemic diarrhea virus.Int J Biol Macromol.2018;117:704-712.

32.Liu D, Li L, Chen J, Chen Z,Jiang L, Yuan C*, Huang M*. Dissociation of zinc phthalocyanine aggregation on bacterial surface is key for photodynamic antimicrobial effect.Journal of Porphyrins and Phthalocyanines.2018, 22, 925-934

31. Li S, Li L, Chen Z, Xue G,Jiang L, Zheng K, Chen J, Li R, Yuan C*, Huang M*. A novel purification procedure for recombinant human serum albumin expressed in Pichia pastoris.Protein Expr Purif.2018;149:37-42.

30.Jiang L, Oldenburg E, Kromann-Hansen T, Xu P, Jensen JK, Andreasen PA, Huang M*. Cleavage of peptidic inhibitors by target protease is caused by peptide conformational transition.Biochim Biophys Acta-General subjects. 2018;1862(9):2017-2023.

29. Buckley BJ, Aboelela A, Minaei E,Jiang L, Xu Z, Ali U, Fildes K, Cheung CY, Cook SM, Johnson DC, Bachovchin DA, Cook GM, Apte M, Huang M, Ranson M*, Kelso M*. 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.J Med Chem.2018;61(18):8299-8320.

28. Xu M, Chen Y, Xu P, Andreasen PA,Jiang L*, Li J*, Huang M*. Crystal structure of plasma kallikrein reveals the unusual flexibility of the S1 pocket triggered by Glu217.FEBS Lett.2018;592(15):2658-2667.

27. Xie X, Xue G,Jiang L*, Huang M*. Ligand Induced Conformational Transitions of Tissue Factor Omega Loop.Chinese J. Struct. Chem.2018; 61(18):2017-2023.

26. Li R, Ma H,Jiang L, Qiao S, Zhi Y, Huang M, Deng R, Zhang G*. The CD163 long-range scavenger receptor cysteine-rich repeat: expression, purification and X-ray crystallographic characterization.Acta Crystallogr F Struct Biol Commun.2018;74(Pt 5):322-326.

25. Jia Y, Li J, Chen J, Hu P,Jiang L, Chen X, Huang M, Chen Z*, Xu P*. Smart Photosensitizer: Tumor-Triggered Oncotherapy by Self-Assembly Photodynamic Nanodots.ACS Appl Mater Interfaces.2018;10(18):15369-15380.

24. Liu Y,Jiang, L, Song L, Tu D, Zheng W, Huang P, Chen M, Chen X*. Deciphering molecular interaction of binaphthyl compounds withPenicillium expansumlipase: enantioselectivity and reactivity prediction for lipase.Molecular Systems Design & Engineering, 2018,3, 658-667

23.Jiang L, Zhang X, Zhou Y, Chen Y, Luo Z, Li J, Yuan C, Huang M*. Halogen bonding for the design of inhibitors by targeting the S1 pocket of serine proteases.RSC Adv.2018;8(49):28189-28197.

22. Liu M, Yuan C, Jensen JK, Zhao B, Jiang Y,Jiang L, Huang M*. The crystal structure of a multidomain protease inhibitor (HAI-1) reveals the mechanism of its auto-inhibition.J Biol Chem. 2017;292(20):8412-8423.

21. Ma H^#,Jiang L^#, Qiao S, Zhi Y, Chen XX, Yang Y, Huang X, Huang M, Li R*, Zhang GP*. The Crystal Structure of the Fifth Scavenger Receptor Cysteine-Rich Domain of Porcine CD163 Reveals an Important Residue Involved in Porcine Reproductive and Respiratory Syndrome Virus Infection.J Virol.2017;91(3):e01897-16.

20. Xue G, Gong L, Yuan C, Xu M, Wang X,Jiang L*, Huang M*. A structural mechanism of flavonoids in inhibiting serine proteases.Food Funct. 2017;8(7):2437-2443.

19. Liu M, Yuan C, Jiang Y,Jiang L, Huang M*. Recombinant hepatocyte growth factor activator inhibitor 1: expression in Drosophila S2 cells, purification and crystallization.Acta Crystallogr F Struct Biol Commun. 2017;73(Pt 1):45-50.

18. Yuan C, Jürgensen HJ, Engelholm LH, Li R, Liu M,Jiang L, Luo Z, Behrendt N, Huang M*. Crystal structures of the ligand-binding region of uPARAP: effect of calcium ion binding.Biochem J.2016;473(15):2359-68.

17.Jiang L, Lin L, Li R, Yuan C, Xu M, Huang JH, Huang M*. Dimer conformation of soluble PECAM-1, an endothelial marker.Int J Biochem Cell Biol. 2016;77(Pt A):102-108.

16.Jiang L, Andersen LM, Andreasen PA, Chen L, Huang M*. Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate.Biochim Biophys Acta-General subjects. 2016; 1860 (3):599-606.

15. Xu P, Xu M,Jiang L, Yang Q, Luo Z, Dauter Z, Huang M, Andreasen PA*. Design of Specific Serine Protease Inhibitors Based on a Versatile Peptide Scaffold: Conversion of a Urokinase Inhibitor to a Plasma Kallikrein Inhibitor.J Med Chem. 2015;58(22):8868-76.

14. Sørensen HP, Xu P,Jiang L, Kromann-Hansen T, Jensen KJ, Huang M, Andreasen PA*. Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide-Protease Fusions.J Mol Biol.2015;427(19):3110-22.

13. Liu Y, Chen M,Jiang L, Song L*. Stereoselective interaction of cinchona alkaloid isomers with bovine serum albumin.Food Chem. 2015;181:170-8.

12.Jiang L, Zhao B, Xu P, Sørensen HP, Jensen JK, Christensen A, Hosseini M, Nielsen NC, Jensen KJ, Andreasen PA, Huang M*. Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues.Int J Biochem Cell Biol.2015;62:88-92.

11. Zhao B, Xu P,Jiang L, Paaske B, Kromann-Hansen T, Jensen JK, Sørensen HP, Liu Z, Nielsen JT, Christensen A, Hosseini M, Sørensen KK, Nielsen NC, Jensen KJ, Huang M, Andreasen PA*. A cyclic peptidic serine protease inhibitor: increasing affinity by increasing peptide flexibility.PLoS One.2014;9(12):e115872.

10. Liu Y, Chen M,Jiang L, Song L*. New insight into molecular interaction of heavy metal pollutant--cadmium(II) with human serum albumin.Environ Sci Pollut Res Int. 2014;21(11):6994-7005.

9. Roodbeen R, Paaske B,Jiang L, Jensen JK, Christensen A, Nielsen JT, Huang M, Mulder FA, Nielsen NC, Andreasen PA*, Jensen KJ*. Bicyclic peptide inhibitor of urokinase-type plasminogen activator: mode of action.Chembiochem.2013;14(16):2179-88.

8. Ngo JC,Jiang L, Lin Z, Yuan C, Chen Z, Zhang X, Yu H, Wang J, Lin L, Huang M*. Structural basis for therapeutic intervention of uPA/uPAR system.Curr Drug Targets.2011 Nov;12(12):1729-43.

7. Hosseini M,Jiang L, Sørensen HP, Jensen JK, Christensen A, Fogh S, Yuan C, Andersen LM, Huang M, Andreasen PA*, Jensen KJ*. Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogs.Mol Pharmacol.2011;80(4):585-97.

6. Lin Z,Jiang L, Yuan C, Jensen JK, Zhang X, Luo Z, Furie BC, Furie B, Andreasen PA, Huang M*. Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1.J Biol Chem.2011;286(9):7027-32.

5.Jiang L*, Svane AS*, Sørensen HP, Jensen JK, Hosseini M, Chen Z, Weydert C, Nielsen JT, Christensen A, Yuan C, Jensen KJ, Nielsen NC, Malmendal A, Huang M, Andreasen PA*. The Binding Mechanism of a Peptidic Cyclic Serine Protease Inhibitor.J Mol Biol.2011;412(2), 235-50.

4.Jiang L, Yuan, C, Chen, H, Wang, Y, Zhao, B, Zhang, X, and Huang, M*, Preparation and structure of a new coagulation factor XI catalytic domain for drug discovery.Chinese J. Struct. Chem. 2011;30 (7), 1021-59.

3. Bian, C., Yuan, C., Chen, L., Meehan, E. J.,Jiang, L., Huang, Z., Lin, L., & Huang, M*. (2010). Crystal structure of a triacylglycerol lipase from Penicillium expansum at 1.3 A determined by sulfur SAD.Proteins, 78(6), 1601–1605.

2.Jiang L, Zhao G, Bian C, Yuan C, Huang Z, Huang M*. Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic Acid and 4-(Aminomethyl-phenyl)-methanol.Chinese J. Struct. Chem.2009; 28(2), pp. 253-259.

1.Jiang, L, Yu H, Yuan C, Wang J, Chen L, Edward J. Meehan, Huang Z, Huang M*. The Crystal Structures of 2-Aminobenzothiazole-based Inhibitors in Complexes with Urokinase-type Plasminogen Activator.Chinese J. Struct. Chem.2009; 28(11):1427-1432.